首页> 外文期刊>BMC Cancer >Randomized clinical trial testing the efficacy and safety of 0.5% colchicine cream versus photodynamic therapy with methyl aminolevulinate in the treatment of skin field cancerization: study protocol
【24h】

Randomized clinical trial testing the efficacy and safety of 0.5% colchicine cream versus photodynamic therapy with methyl aminolevulinate in the treatment of skin field cancerization: study protocol

机译:随机临床试验测试0.5%秋水仙碱霜与光动力学疗法联合氨基乙酰丙酸甲酯在治疗皮肤癌中的功效和安全性:研究方案

获取原文
获取外文期刊封面目录资料

摘要

The primary clinical manifestation of skin field cancerization is the presence of actinic keratoses (AKs). Current treatments for AKs related to skin field cancerization include photodynamic therapy (PDT) and colchicine. The objective of this study is to evaluate the efficacy and safety of 0.5% colchicine cream versus PDT with methyl aminolevulinate (MAL-PDT) in the treatment of skin field cancerization. In a randomized controlled and open clinical trial with a blind histopathological and immunohistochemical analysis, 36 patients with up to 10 AKs on their forearms will be included from the outpatient clinic. The forearms will be randomized into two groups, clinically evaluated and biopsied for histopathology and immunohistochemistry (p53 and Ki67). One forearm will be treated with 0.5% colchicine cream for 10?days, and the other forearm will receive one session of MAL-PDT; the forearms will subsequently be reassessed clinically and histologically after 60?days (T60) of treatment. The primary endpoint will be the point of complete clearance of AKs in T60. The sample size will enable a detection in the reduction of over 10% in AK counts between the groups with power of 0.9 and an alpha of 0.05, accounting for an estimated dropout rate of 10%, resulting in 36 patients (72 forearms). All participants included in the randomized study will be part of the analysis, and the final outcomes of any dropouts will be the value of their last visit (LOCF). The statistical analysis will be performed using SPSS 22.0, and a p value
机译:皮肤癌的主要临床表现是光化性角化病(AKs)的存在。与皮肤癌相关的AK的当前治疗方法包括光动力疗法(PDT)和秋水仙碱。这项研究的目的是评估0.5%秋水仙碱乳膏与PDT和氨基乙酰丙酸甲酯(MAL-PDT)的疗效和安全性。在一项随机对照和开放式临床试验中,采用盲法组织病理学和免疫组化分析,将包括36名前臂上具有多达10个AK的患者。前臂将随机分为两组,进行临床评估和活组织检查和免疫组织化学检查(p53和Ki67)。一个前臂将接受0.5%秋水仙素乳膏治疗10天,另一只前臂将接受一次MAL-PDT治疗。治疗60天(T60)后,将在临床和组织学上重新评估前臂。主要终点将是T60中AK完全清除的点。样本量将能够检测出两组之间的AK计数降低10%以上,功效为0.9,α为0.05,估计辍学率为10%,从而导致36例患者(72个前臂)。随机研究中包括的所有参与者将成为分析的一部分,任何辍学的最终结果将是他们上次访问(LOCF)的价值。将使用SPSS 22.0进行统计分析,并且p值<?5%被认为是重要的。预期秋水仙碱在减少AKs和皮肤癌变方面将优于MAL-PDT,并且两组均具有良好的耐受性。秋水仙碱干预是新颖的,因为它为MAL-PDT提供了新的替代方法。此外,这种药物价格便宜,可以作为皮肤癌的潜在治疗方法,可以在公共卫生系统中开出良好的疗效。该试验已在巴西临床试验注册中心注册(注册号:RBR-8y3sj9,日期为2016年5月4日,追溯注册)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号